Hepatitis B Vaccination Guidelines

Introduction

• Hepatitis B vaccination is recommended for all individuals, with specific guidelines for different populations, such as infants, healthcare personnel, and immunocompromised individuals, as supported by the Centers for Disease Control and Prevention (CDC) and the American College of Physicians 1, 2, 3

Vaccination Schedule and Efficacy

• The CDC recommends a standard 3-dose vaccination series at 0, 1, and 6 months to achieve optimal protection against Hepatitis B in non-immune individuals, producing a protective antibody response in 30-55% of healthy adults after the first dose, 75% after the second dose, and >90% after the third dose in adults under 40 years, with a strength of evidence rated as high 3
• Age significantly impacts vaccine response rates, with adults under 40 years having >90% develop protective antibodies after 3 doses, adults 40-60 years having approximately 75-90% develop protection, and adults over 60 years having approximately 75% develop protection, as noted by the CDC 3
• Protection against symptomatic and chronic HBV infection has been documented to persist for ≥22 years in vaccine responders, even if antibody levels decline over time, with a strength of evidence rated as moderate 3

Special Populations

• Hematopoietic stem cell transplant recipients should receive three doses of hepatitis B vaccine administered 6-12 months post-transplant, and if protective antibody levels are not achieved, a second 3-dose series should be administered, as recommended by the Infectious Diseases Society of America 4
• Solid organ transplant candidates should complete vaccination before transplantation, with a strength of evidence rated as high 4
• Infants born to HBsAg-positive mothers should receive the hepatitis B vaccine at 0, 1, 6 months PLUS Hepatitis B Immune Globulin (HBIG) within 12 hours of birth, according to the CDC guidelines, with a strength of evidence rated as high 2
• Low birthweight infants (<2,000g) should follow a modified schedule based on maternal HBsAg status, with the first dose at birth (≤12 hrs) + HBIG, second dose at 1 month, third dose at 2-3 months, fourth dose at 6 months if the mother is HBsAg-positive, as recommended by the CDC, with a strength of evidence rated as moderate 2
• Hemodialysis patients should receive a 4-dose schedule at 0, 1, 2, and 6 months with a 40 mcg/2.0 mL dose, according to the CDC guidelines, with a strength of evidence rated as high 2
• Adolescents aged 11-15 years may receive the adult formulation of Recombivax HB (10 μg) in a 2-dose schedule at 0 and 4-6 months, as recommended by the CDC, with a strength of evidence rated as moderate 2, 5
• Adults can receive a 3-dose series of Hepatitis B vaccine at 0, 1, and 6 months, with options including Engerix-B, Recombivax HB, PreHevbrio, Heplisav-B, and Twinrix, each with specific dosing schedules, as recommended by the CDC, with a strength of evidence rated as high 6

Vaccine Administration and Follow-up

• The American College of Physicians does not recommend more than two complete vaccine series in non-responders, and a single challenge dose of hepatitis B vaccine should be administered as the first step, followed by testing anti-HBs levels 4-8 weeks after the challenge dose, with a strength of evidence rated as moderate 3, 7
• Post-vaccination testing is recommended for infants born to HBsAg-positive mothers (test at 9-15 months) and hemodialysis patients (annual testing), but not routinely recommended for healthy individuals, according to the CDC guidelines, with a strength of evidence rated as high 2
• Routine post-vaccination serologic testing is not recommended for most adults, but is essential for individuals with non-reactive titers after initial doses to confirm protection, with a goal of achieving anti-HBs ≥10 mIU/mL, which is considered protective, as recommended by the CDC, with a strength of evidence rated as moderate 2, 8
• The CDC recommends a booster dose when anti-HBs levels decline below 10 mIU/mL, and annual antibody testing is recommended for individuals at ongoing risk, such as healthcare personnel, hemodialysis patients, HIV-infected persons, and other immunocompromised individuals, with a strength of evidence rated as high 2

Common Errors in Vaccination

• Incorrect injection site, inadequate follow-up, premature abandonment, and ignoring risk factors such as smoking, obesity, genetic factors, and immune suppression can reduce vaccine response, as noted by the CDC, with a strength of evidence rated as moderate 3
• The hepatitis B vaccine should be administered in the deltoid muscle to ensure optimal immunogenicity, according to the ACIP recommendations, while neonates and infants should receive the vaccine in the anterolateral thigh, with buttock injections avoided due to significantly lower immunogenicity, with a strength of evidence rated as high 2, 1

Co-administration with Other Vaccines

• Minimum intervals and recommended spacings for co-administration with other vaccines are as follows:

  Vaccine	Minimum Interval	Recommended Spacing
  Hepatitis A	-	6-18 months apart
  MMR	4 weeks	≥4 weeks
  Varicella (under 13 years)	28 days	3 months
  Varicella (13 years and older)	4 weeks	4 weeks
  HPV	4 weeks (first and second doses), 12 weeks (second and third doses)	0, 1-2, and 6 months
  Tdap/Td	4 weeks	4 weeks
  COVID-19	3-4 weeks (depending on vaccine type)	4-8 weeks (Moderna), 3-8 weeks (Pfizer), 3-8 weeks (Novavax)
  Zoster (Shingrix)	4 weeks	2-6 months

Duration of Protection

• Children who complete the 3-dose hepatitis B vaccination series maintain protection against clinical disease and chronic hepatitis B infection for at least 20 years, even if antibody levels decline, as noted by the CDC, with a strength of evidence rated as high 12
• Protection has been demonstrated to persist for at least 4 years in follow-up studies, although the duration of protection may vary depending on individual factors, such as age >40 years, smoking, obesity, and immune suppression, which can reduce vaccine response, with a strength of evidence rated as moderate 8, 3, 13, 14

Pregnancy and Immunocompromised Individuals

• Pregnancy is not a contraindication for HBV vaccination, and there is no apparent risk to developing fetuses, as recommended by the CDC, with a strength of evidence rated as high 1
• Individuals with immunosuppression or other immunocompromising conditions may require modified dosing regimens, including doubling the standard antigen dose or additional doses, as recommended by the Infectious Diseases Society of America, with a strength of evidence rated as moderate 5, 4